Phorbol 12,13-dibutyrate (P(Bu)2)-treated human blood mononuclear cells bind to each other

Cellular Immunology
M PatarroyoG Klein

Abstract

Treatment of human blood mononuclear cells with nanomolar concentrations of phorbol 12,13-dibutyrate (P(Bu)2) induced their aggregation. The phenomenon was seen within a few minutes and reached its maximum manifestation after 20 min. At this time, 20-30% of unfractionated and nylon wool-passed mononuclear leukocytes were in the aggregates. The influence of pretreatment with 2-deoxyglucose, NaN3, EDTA, cyclohexamide, or incubation at 4 degrees C on the phenomenon indicated that it is energy and temperature dependent, requires the presence of extracellular divalent cations, and is independent of protein synthesis. Nonaggregating 2-deoxyglucose-and NaN3-pretreated cells could still bind [3H]P(Bu)2 which rules out the possibility that the phorbol ester molecule acts as a bridge between the aggregated cells. Seventeen percent of the P(Bu)2-treated T-cell population bound untreated autologous and allogeneic cells. The binding property has a certain species specificity because only 4% of the cells interacted with mouse lymphocytes. At the ultrastructural level, the intercellular binding showed broad areas of surface contact (both between lymphocytes and lymphocyte-monocyte) and "trapping" by surface processes was not seen. Aggregated ...Continue Reading

References

Oct 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J Lotem, L Sachs
Feb 1, 1977·The Journal of Experimental Medicine·J L TouraineR A Good
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·U GaliliE Klein
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·A D HorowitzI B Weinstein
Sep 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·T EnomotoH Yamasaki
Dec 15, 1982·International Journal of Cancer. Journal International Du Cancer·M PatarroyoG Klein
Jan 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P E Driedger, P M Blumberg
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·K Nagasawa, T W Mak
Feb 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·J J SandoJ J Farrar
Jan 15, 1982·International Journal of Cancer. Journal International Du Cancer·D DeliaG Goldstein

❮ Previous
Next ❯

Citations

Dec 15, 1988·Biochemical and Biophysical Research Communications·G SkoglundM Ingelman-Sundberg
Apr 1, 1990·Immunological Reviews·M PatarroyoC G Gahmberg
Sep 1, 1990·Scandinavian Journal of Immunology·T A Springer
Dec 1, 1985·Scandinavian Journal of Immunology·M PatarroyoC G Gahmberg
Sep 1, 1989·European Journal of Immunology·J PrietoM Patarroyo
Oct 15, 1986·International Journal of Cancer. Journal International Du Cancer·M PatarroyoC G Gahmberg
Jan 1, 1989·Rheumatology International·D O HaskardM Ziff
Aug 1, 1989·Scandinavian Journal of Immunology·M Patarroyo, M W Makgoba
May 1, 1992·Clinical and Experimental Immunology·M R PadrosL Fainboim
May 1, 1988·Cellular Immunology·M PatarroyoC G Gahmberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.